Sermorelin: the growth-hormone peptide that was a real FDA drug — twice

Most peptides on the longevity shelf have never been near an FDA filing. Sermorelin has two. It was a real prescription drug — sold in a box, dosed in clinics, pulled for business reasons rather than because it failed. And it started life doing something almost nobody mentions now: it was a test before it was a treatment.

That paper trail is why people trust it. The reason they want it is simpler. Sermorelin asks your own gland to make more growth hormone instead of piping the hormone in from outside. It works with the system, not over the top of it. This page is the map — what it is, what it did in the clinic, and where it stands today.

What sermorelin actually is

Sermorelin is a short peptide, 29 amino acids long. It’s the front end of a signal your own body already makes.

Your brain releases GHRH to tell the pituitary — a gland the size of a pea, tucked behind your eyes — to let go of a pulse of growth hormone. Native GHRH is 44 building blocks. Sermorelin is the first 29 of them, the working end that grabs the receptor and flips the switch. Everything after that is your own machinery doing its own job.

That’s the whole design idea. Don’t flood the body with growth hormone from a needle. Nudge the gland to fire a little more often, the way it did a decade ago, and let your natural rhythm of release stay roughly intact. For anyone wary of the blunt-instrument feel of raw growth hormone, that gap is the appeal.

The deep version of that appeal — what turning the dial might actually do for a healthy forty-year-old, and how far the human proof goes — lives on its own page: sermorelin, the older growth-hormone peptide that still has defenders. What follows here is the outline.

The one on this shelf that was a real drug

This is where sermorelin stops resembling the rest of the shelf. It cleared the FDA. Not once — twice.

It sold as Geref, made by Serono, under two separate approvals. NDA 019863, approved December 1990, was a diagnostic — one injection to see whether a struggling pituitary could still produce growth hormone on cue. NDA 020443, approved September 1997, was a treatment for children who weren’t making enough growth hormone of their own. A test, then a therapy. Both went the full distance through the process.

Then Serono walked away. Geref left the US market in 2008, and the FDA formally withdrew both approvals effective June 18, 2009 — for commercial reasons, stated on the record, not safety or efficacy. The molecule kept its record. Only the business behind the brand didn’t. That’s why endocrinology clinics still compounding it call it the legitimate one, and on paper they have a point.

What the human evidence actually covers

Now the honest part, kept short.

The people the FDA studied weren’t middle-aged men chasing a tune-up. Geref was proven in growth-hormone-deficient kids and used as a diagnostic. The published adult work is thin, and it sits in a different group again — older adults, not forty-somethings.

Vittone and colleagues, in 1997, gave nightly injections of GHRH (1-29) — the sermorelin sequence — to healthy elderly men and watched their growth hormone and IGF-1 numbers climb. A longer study that same year by Khorram and colleagues did much the same over a sustained run. One detail worth carrying: that second study used a stabilised cousin of sermorelin, not the strict molecule. It’s a common trap in the 1990s GHRH literature, where close analogs get quietly filed under the sermorelin name. The dial moves. That much is real. Whether moving it changes anything you’d feel, in your age group, over years — that trial hasn’t been run. The anti-aging page walks through how big that gap is.

Where the regulation sits

Sermorelin’s position is quietly comfortable. It’s not on the FDA’s July 2026 PCAC wave, and it’s not on the second wave scheduled before the end of February 2027 either — checked against the April 2026 Federal Register notice. It was never voted down by the committee, either, unlike some of its growth-hormone cousins. Because its active ingredient already cleared the FDA years ago, sermorelin runs under the established drug-and-compounding rules, not the bulk-substance review the newer peptides are still waiting on. What a PCAC review actually decides is a longer story, told in what a PCAC review actually is. The short version: sermorelin’s availability doesn’t hinge on this summer’s vote.

Anti-doping is the blunt line. Sermorelin is a GHRH analog, and WADA bans that entire class under S2 — in and out of competition. If you compete, treat it as prohibited, and check the current code on the day.

Where this leaves you

Sermorelin is the most documented name in the growth-hormone-peptide class, full stop. It went through the whole drug process and came out with a record nothing else on the shelf can match. The catch is who that record was built on: deficient kids and older adults, not the middle-aged men reaching for it now. The pedigree is real. The proof for the use people actually want is still outstanding.

That gap is exactly why how you get it matters more than the molecule. Off a research-chemical site, you’re trusting a stranger that the vial holds sermorelin and not a cheaper look-alike, at the strength on the label, made clean. Nobody to ask. Nothing to check.

A legitimate version answers those questions before you ever inject: a physician with a real reason to prescribe, a US-licensed pharmacy making the actual molecule, a test run on every batch. That’s the standard Wolverine Health is being built to hold. It can’t open until the science and the rules catch up, and that’s the honest reason it hasn’t yet. Leave your email. The day sermorelin is something you can order the right way, you’ll hear it from us first.